Stockscreener 앱 받기
5.095
3.32%
-0.175
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38 - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RA Capital Management Acquires 1,914,788 Shares of Corbus Pharmaceuticals (CRBP) - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Four parties report the same Corbus (CRBP) stake, held directly by one fund. - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
EBITDA of Corbus Pharmaceuticals Holdings Inc – HAN:3371 - TradingView
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - finance.yahoo.com
About 14,000 U.S. patients may qualify yearly for another throat cancer treatment. Corbus doses its first trial patient. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - Kalkine Media
(CRBP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings (Nasdaq:CRBP)Stock Analysis - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP - Finviz
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss TherapySlideshow (NASDAQ:CRBP) 2026-09-17 - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Corbus Pharmaceuticals Announces Positive Topline Data from - GlobeNewswire
Corbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial Data - finance.yahoo.com
Corbus Pharmaceuticals Announces Positive Topline Data from - GlobeNewswire
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - Yahoo Finance
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Corbus Pharmaceuticals to Host Sept. 14 Webcast on Topline CANYON-1 Phase 1b Data for CRB-913 in Obesity - Quiver Quantitative
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo! Finance Canada
Corbus Pharmaceuticals to Host Conference Call to Discuss - GlobeNewswire
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - Yahoo Finance
1.94%
자본화:
|
볼륨(24시간):